Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Triple Negative Breast Neoplasms 2Pancreatic Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 15camrelizumab 11Capecitabine 11130-nm albumin-bound paclitaxel 10pembrolizumab 8eribulin 8Paclitaxel 8Cyclophosphamide 8Epirubicin 7Gemcitabine 6Cisplatin 6tislelizumab 5apatinib 5atezolizumab 4anlotinib 4Taxes 4Nivolumab 4Docetaxel 4Bevacizumab 4toripalimab 3Vinorelbine 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Doxorubicin 3Albumin-Bound Paclitaxel 3talazoparib 2spartalizumab 2olaparib 2fluzoparib 2famitinib 2Zoledronic Acid 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Triple Negative Breast Neoplasms × AZD 6244 × Clear all
NCT02583542 2020-02-25

TORCMEK

Queen Mary University of London

Phase 1/2 Unknown
118 enrolled
Breast

Triple Negative Breast Neoplasms

NCT02685657 2016-02-22

Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer

Russian Academy of Medical Sciences

Phase 2 Unknown
164 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡